Description

Remestip (terlipressin acetate) solution for injections 0.1 mg/ml. ampoules 2 ml. №5

Ingredients:

Each 2 ml ampoule contains 0.1 mg of terlipressin acetate as the active ingredient.

Dosage:

The recommended dosage of Remestip is determined by a healthcare professional and administered via intravenous injection.

Indications:

Remestip is indicated for the treatment of hepatorenal syndrome, a serious complication of advanced liver disease.

Contraindications:

Do not use Remestip in patients with known hypersensitivity to terlipressin or any other component of the formulation.

Directions:

Remestip should be administered under the supervision of a healthcare provider experienced in the treatment of hepatorenal syndrome.

Scientific Evidence:

Terlipressin, the active ingredient in Remestip, is a synthetic analog of vasopressin that acts as a systemic vasoconstrictor. It has been shown to improve renal function in patients with hepatorenal syndrome by increasing renal perfusion and reducing splanchnic blood flow.

Clinical trials have demonstrated the efficacy of terlipressin in improving renal function and reducing mortality in patients with hepatorenal syndrome compared to placebo or other vasoconstrictor agents.

Additional Information:

Remestip is a crucial treatment option for patients with hepatorenal syndrome, offering a targeted approach to improve renal function and outcomes in this high-risk population. It is essential to closely monitor patients receiving Remestip for any adverse reactions or changes in renal function.

Consult the prescribing information and guidelines for detailed dosing recommendations and precautions when using Remestip in clinical practice.